Senju Pharmaceutical Co Ltd - Company Profile
Powered by 
All the data and insights you need on Senju Pharmaceutical Co Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date Senju Pharmaceutical Co Ltd Strategy Report
- Understand Senju Pharmaceutical Co Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Senju Pharmaceutical Co Ltd (Senju) research, develops, manufactures and markets pharmaceutical products for eye, ear, nose, throat and skin. The company offers a wide range of ophthalmological products. Its product portfolio includes prescription products, OTC medicines and veterinary drugs. Senju offers prescription products in the areas of allergy, inflammation, glaucoma, cataract, protection of cornea, infection, and surgical aid. The company’s OTC medicines include ophthalmological drugs such as eye drops, contact lens preparations and eye solutions; and animal science drugs include both animal pharmaceuticals and aqua products. It operates research laboratories and manufacturing facilities in Japan and the US. The company exports its products in Asia, North and South America, Europe, and Middle East. Senju is headquartered in Chuo, Osaka, Japan.
Headquarters
Japan
Address
3-1-9, Kawara-Machi, Chuo, Osaka, 541-0048
Website
www.senju.co.jp
Telephone
81 6 62012512
No of Employees
922
Industry
Pharmaceuticals and Healthcare
Senju Pharmaceutical Co Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Prescription | Bronuck |
| Inflammation | Niflan |
| Glaucoma | Odomel |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Official Trials/Tests | In March, the company announced the Phase III trials for SJP-0132. |
| 2023 | Contracts/Agreements | In February, the company announced its collaboration with Alcchemedicine to discover and optimize drug candidate for the company target of interest. |
| 2022 | New Products/Services | In November, the company announced the launch and distribution of Soft-MIEr and MIEr for Claio. |
Competitor Comparison
| Key Parameters | Senju Pharmaceutical Co Ltd | Taisho Pharmaceutical Holdings Co Ltd | Nichi-Iko Pharmaceutical Co Ltd | Zeria Pharmaceutical Co Ltd | Daito Pharmaceutical Co Ltd |
|---|---|---|---|---|---|
| Headquarters | Japan | Japan | Japan | Japan | Japan |
| City | Chuo | Toshima-Ku | Toyama-Shi | Chuo-Ku | Toyama-Shi |
| State/Province | Osaka | Tokyo | Toyama | Tokyo | Toyama |
| No. of Employees | 922 | 8,784 | 2,656 | 1,729 | 1,011 |
| Entity Type | Private | Private | Private | Public | Public |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Yukoh Yoshida | Chairman | Executive Board | - | - |
| Shuhei Yoshida | President; Chief Executive Officer | Senior Management | - | - |
| Takuro Sekiya | General Manager - Research and Development Headquaters | Senior Management | - | - |
| Kozo Ito | General Manager - Pharmaceutical Market Division | Senior Management | - | - |
| Mitsuhei Nishio | General Manager - Production Headquaters | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer